FOLH1 and neoplasm: Preclinical studies utilizing cell-based in vitro assays have indicated higher efficacy of 161Tb over 177Lu 27-30, a dose-dependent delay in tumor growth and a prolonged survival in mice treated with [161Tb]Tb-PSMA-617 were observed 31.